U.S. Controlled Substance Companies and Development Strategy

Top Companies in the U.S. Controlled Substance Market

• AbbVie, Inc.
• Pfizer, Inc.
• Merck & Co., Inc
• Mallinckrodt plc
• F. Hoffmann-La Roche AG
• Janssen Pharmaceuticals, Inc.
• Purdue Pharma L.P.
• Teva Pharmaceutical Industries Ltd.
• Other Prominent Players

Market Growth

The U.S. Controlled Substance Market size is estimated at US$ 52.3 billion in 2024, is projected to grow to US$ 55 billion in 2025, and is expected to reach around US$ 84.95 billion by 2034. The market is projected to expand at a CAGR of 5.24% between 2025 and 2034.

U.S. Controlled Substance Market Trends

Increasing government initiative, such as the National Action Plan for Drug Demand Reduction (NAPDDR), through which the Government is making a sustained and coordinated action to arrest the problem of substance abuse, which drives the growth of the market.

For instance,

• In August 2025, the Drug Enforcement Administration announces a major new initiative to strengthen collaboration between the United States and Mexico in the fight against cartels, whose trafficking networks are responsible for flooding American communities with deadly synthetic drugs.

Increasing awareness related to applications of controlled substances, which drives the growth of the market.

For Instance,

• In June 2025, the state government launched a statewide awareness campaign to fight drug abuse, especially among youths.

U.S. Controlled Substance Market – Value Chain Analysis

R&D

In R&D processes of controlled substances in discovery and development, preclinical research, clinical research, FDA drug review, and FDA post-market safety monitoring

Key Players:  Pfizer and Merck

Clinical Trials

Clinical trials of controlled substances are increasing as pharmaceutical companies examine the potential medicinal value of cannabis-derived complexes. Many companies are directing various indications of controlled substances that previously received U.S. Food and Drug Administration (FDA) approval.

Key Players:  Illumina, Inc. and Avammune Therapeutics.

Patient Support and Services

Proper opioid prescribing necessitates a thorough patient assessment, short and long-term therapy planning, regular follow-up, and continuous monitoring.

Key Players: Eli Lilly and Co. and AbbVie Inc

Latest Announcements by Industry Leaders

In June 2025, Karen Kobelski, Vice President and General Manager for Clinical Surveillance at Wolters Kluwer Health, said, “Invistics’ advanced technology solution fits perfectly with our existing offerings, such as Simplifi+ and Sentri7, which help customers achieve optimal clinical outcomes and regulatory compliance. Our efforts to help health systems deploy effective pharmacy surveillance and compliance programs to reduce patient risk are further enhanced by incorporating the Invistics solution."

Recent Developments in the U.S. Controlled Substance Market

• In September 2025, PillSafe, a leader in smart medication management technology, announces it will open an initial investment round via a SAFE offering, with a commercial launch in 2026. The patented solution secures prescriptions from pharmacy to medicine cabinet, addressing a $500+ billion problem in avoidable annual costs, medication nonadherence, and controlled substance misuse in the U.S.
• In June 2025, George Medicines, a late-stage biopharmaceutical company focused on addressing unmet needs in cardiometabolic disease, announces that the US Food and Drug Administration (FDA) has approved WIDAPLIK, formerly known as “GMRx2”, for the treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure.
• In June 2025, Supernus Pharmaceuticals, Inc. and Sage Therapeutics, Inc. announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash, payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash, for total consideration of $12.00 per share in cash
• In April 2025, the US Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com